- Molecular NameEverolimus
- Synonymeverolimus
- Weight958.24
- Drugbank_IDDB01590
- ACS_NO159351-69-6
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)8.13
- pkaN/A
- LogD (pH=7, predicted)8.13
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.71
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)1.89
- No.of HBond Donors3
- No.of HBond Acceptors15
- No.of Rotatable Bonds9
- TPSA204.66
- StatusFDA approved
- AdministrationN/A
- PharmacologyA derivative of Rapamycin (sirolimus) (the structure can be written as 42-O-(2-hydroxyethyl)rapamycin), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding73.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmEverolimus is metabolized by cytochrome P4503A and 2C8 enzymes to numerous hydroxylated and/or demethylated metabolites. The yield of the major, pure metabolites was: 18.3 ug 46-hydroxy, 20.8 ug 24-hydroxy, and 23.9 ug 25-hydroxy everolimus; the yield of all other metabolites was less than 10 ug.
- Half life~30 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A